Silgan Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLGN research report →
Range $38 – $59
Price Chart
About the company
Silgan Holdings Inc. , along with its affiliates, manufactures and distributes rigid packaging solutions for consumer products across North America, Europe, and other global markets. The company operates through three principal divisions.
- CEO
- Adam J. Greenlee
- IPO
- 1997
- Employees
- 17,320
- HQ
- Norwalk, CT, US
Get TickerSpark's AI analysis on SLGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.19B
- P/E
- 15.98
- Fwd P/E
- 10.25
- PEG
- -1.00
- P/S
- 0.62
- P/B
- 1.69
- EV/EBITDA
- 9.12
- Div Yield
- 2.09%
- Gross Margin
- 17.01%
- Op Margin
- 9.36%
- Net Margin
- 3.90%
- ROE
- 11.09%
- ROIC
- 5.26%
Latest fiscal year · YoY change
- Revenue
- $6.48B+10.7%
- Gross Profit
- $1.15B+13.6%
- Op Income
- $658.38M
- Net Income
- $288.40M+4.4%
- EPS
- $2.71+4.6%
- OCF Growth
- +1.1%
- FCF Growth
- -7.9%
- 52W High
- $57.04
- 52W Low
- $33.70
- 50D MA
- $38.36
- 200D MA
- $41.21
- Beta
- 0.64
- RSI (14)
- 48
- Avg Volume
- 1.13M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Silgan delivered a strong third quarter with record adjusted EPS, raised full-year guidance again, and said its faster-growing dispensing and pharma businesses are offsetting softer consumer demand in parts of food and beverage.· October 29, 2026
- 3Q adjusted EPS was $1.31, up 7% year over year and at the top of management’s expected range.
- Net sales were about $2 billion, up 2%, while adjusted EBIT was $235 million, up 6% year over year.
- Full-year 2026 adjusted EPS guidance was raised to $3.83 to $3.93, implying low-single-digit adjusted EBIT growth and about $450 million of free cash flow.
- Dispensing and Specialty Closures benefited from growth in fragrance and prescription pharma, with pharma up double digits in North America.
- Management said consumer pressure persists in food and beverage, especially soup, but Q4 should show some inflation recovery and year-over-year EBIT growth in DSC.
Reported 3Q 2026 net sales were approximately $2 billion, up 2% year over year. Adjusted EBIT was $235 million, up 6%, and adjusted EPS was $1.31, up 7% versus the prior-year quarter. For segments, Dispensing and Specialty Closures sales rose 1% and adjusted EBIT was down $2 million; Metal Container sales rose 1% and adjusted EBIT was $9 million above the prior year; Custom Containers sales rose 4% and adjusted EBIT was above the prior year. For 4Q 2026, management guided to adjusted EPS of $0.76 to $0.86 versus $0.67 a year ago, with adjusted EBIT up about $10 million to $15 million year over year, interest expense of $45 million to $50 million, and a tax rate of about 25% to 26%. For full-year 2026, adjusted EPS guidance was raised to $3.83 to $3.93 versus $3.72 in 2025, with low-single-digit adjusted EBIT growth, adjusted corporate expense of about $45 million to $50 million, interest expense of about $185 million, and free cash flow confirmed at about $450 million, including about $310 million of CapEx. Volumes are now expected to be comparable to the prior year in all three segments for both 4Q and full-year 2026.
Adam Greenlee framed the quarter as another proof point that Silgan can grow earnings despite a tougher consumer backdrop, cost inflation, and currency pressure. He emphasized mid-single-digit growth in fragrance and pet food, double-digit growth in prescription pharma in North America, and improving profitability in Metal Containers and Custom Containers. He also struck a confident tone on 2027, saying the company is positioned for another year of organic earnings and free cash flow growth and that the Trivium-related reorganization should sharpen each business’s strategic focus.
Shawn Fabry said 3Q adjusted EPS came in at the top of the company’s expected range because of strong operating EBIT in each segment and favorable interest expense, partly offset by a higher tax rate. He cited the quarter’s approximately $2 billion in sales, $235 million of adjusted EBIT, and the segment-level mix of higher pricing pass-throughs plus lower or flat volumes depending on the business. On outlook, he reiterated 4Q adjusted EPS of $0.76 to $0.86 and the full-year 2026 range of $3.83 to $3.93, while confirming about $450 million of free cash flow and about $310 million of CapEx. He also said interest expense should be roughly comparable year over year for the full year after active treasury work and better working-capital management.
Analysts pressed on whether consumer demand had weakened further and whether soup and other food categories would recover; management said the softness is a continuation of what they have been seeing, with some customers promoting and others passing through inflation, and no one-size-fits-all pattern. Questions on DSC margins and inflation recovery drew the response that Q4 should show normalization as pricing actions start to flow through, with some lagged recovery into 2027. Analysts also asked about pharma growth, and management said the business is about a $250 million revenue opportunity, runs on 3- to 5-year development/regulatory pipelines, and should keep growing as launches progress. On the Trivium deal, management said the transaction is designed to be leverage neutral and should not distract from pharma growth or other capital deployment efforts.
The bull case from this call is that Silgan continues to grow earnings and cash flow even without broad end-market growth. Management pointed to durable wins in higher-growth areas like fragrance and pharma, plus improved cost structure and pricing recovery that should help margins into Q4 and beyond. The proposed portfolio split into Silgan DS and Silgan MCC is presented as a way to make the faster-growing businesses more visible and better positioned over time.
The main risks discussed were soft consumer demand in food and beverage, especially soup, plus inflation and pass-through timing in dispensing. Management also flagged softness in Brazil and noted that some margin recovery depends on pricing actions flowing through over the next couple of quarters, which means some pressure can linger into 2027. The Trivium transaction will require incremental investment and integration planning, and management did not size those costs yet.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.7%
- Shares Outstanding
- 105.68M
- Float Shares
- 88.44M
of shares held by institutions
353 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SLGN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Jan 5, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jan 15, 26 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Apr 9, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 16, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Apr 28, 23 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Oct 22, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Oct 19, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jun 19, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 15, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Apr 23, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 10.20M | ▼ 5.65M |
| Vanguard Group Inc | 8.68M | ▼ 247.35K |
| Blackrock, Inc. | 8.18M | ▲ 221.37K |
| Jpmorgan Chase & Co | 6.24M | ▼ 2.85M |
| Fuller & Thaler Asset Management, Inc. | 5.87M | ▲ 1.31M |
| Dimensional Fund Advisors LP | 5.83M | ▲ 499.76K |
| Vanguard Portfolio Management LLC | 4.91M | ▲ 71.99K |
| Vanguard Capital Management LLC | 4.05M | ▲ 10.38K |
| State Street Corp | 3.90M | ▼ 2.66K |
| Millennium Management LLC | 2.80M | ▲ 841.01K |
| Invesco Ltd. | 2.39M | ▲ 14.55K |
| Bank Of America Corp | 2.19M | ▼ 335.88K |
Held by 442 ETFs
Biggest fund positions in SLGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | LEWIS ROBERT B | sell | 28,564 |
| Nov 18, 26 | LEWIS ROBERT B | sell | 25,456 |
| Nov 20, 26 | LEWIS ROBERT B | sell | 11,048 |
| May 27, 26 | Ramdev Niharika | other | 3,254 |
| May 27, 26 | Cleland Nielsen Fiona | other | 3,254 |
| May 27, 26 | Miller Shannon | other | 3,254 |
| May 27, 26 | LICH BRAD A | other | 3,254 |
| May 27, 26 | LEWIS ROBERT B | other | 3,254 |
| May 27, 26 | DONOVAN WILLIAM T | other | 3,254 |
| May 27, 26 | ALLOTT ANTHONY J | other | 3,254 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SLGN coverage
Recent articles, reports, and earnings notes.
Want a deeper read on SLGN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Here's Why Silgan Holdings (SLGN) is a Strong Value Stock
zacks.com · Nov 20
Silgan: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 18
Here's Why Silgan Holdings (SLGN) is a Strong Momentum Stock
zacks.com · Nov 10
Silgan Declares Quarterly Dividend
businesswire.com · Nov 3
Here's Why Silgan Holdings (SLGN) is a Strong Value Stock
zacks.com · Nov 3
What Silgan (SLGN) Said on Its Q3 Earnings Call
marketbeat.com · Oct 31
Silgan Holdings Inc. (SLGN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Silgan (SLGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
